Eltrombopag for Chronic Immune Thrombocytopenia

Efficacy and Safety

The American Society of Hematology recommends eltrombopag as a second-line or third-line therapy option for adult and pediatric patients with chronic immune thrombocytopenia who have had insufficient response to first-line treatments, with a platelet response rate of 70% 1, 2
Eltrombopag achieves platelet responses in 70% of patients with a favorable safety profile, with 59-70% response rates demonstrated in pivotal trials 1, 2
The European Hematology Association notes that more than 80% of patients receiving 50 mg daily of eltrombopag showed increased platelet counts by day 15, with a rapid response typically occurring within 1-4 weeks of treatment initiation 1, 3

The standard starting dose of eltrombopag is 50 mg orally once daily, which can be titrated between 25-75 mg daily based on platelet response, according to the National Comprehensive Cancer Network 1, 3
The International Society on Thrombosis and Haemostasis recommends monitoring platelet counts weekly until stable counts ≥50 × 10⁹/L are achieved, then monthly thereafter, with liver function tests at baseline and regularly throughout therapy 4

The American College of Clinical Pharmacy notes that common adverse events with eltrombopag include headache, which is the most frequent adverse event, occurring in ≥20% of patients 1, 3, 5
Serious adverse events requiring monitoring include hepatotoxicity, with liver function abnormalities occurring in approximately 5-13% of patients, and thrombosis, with treatment-related thrombotic events occurring in 2-3% of patients in clinical trials, according to the American Society of Hematology 1, 4

The European Hematology Association recommends that if considering discontinuation after stable response ≥6 months, taper gradually rather than stopping abruptly to minimize rebound thrombocytopenia, with approximately 30% of patients may achieve sustained remission ≥6 months after discontinuation 1, 5, 7